CALR and myeloproliferative disorder: In CLL, ATM deficiency correlated with olaparib sensitivity [73], and in MPN, JAK2V617F, CALR (del52), MPL (W515L) identified patient samples most likely to benefit from combined therapy with ruxolitinib and hydroxyurea [94].